All In Biotech

Drug Trial Radar · NCT06763965

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection With Recurrent/Progressive High-grade Glioma.

Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

30

Planned (sponsor's estimate)

Start

Nov 26, 2024

Primary completion

Jul 31, 2027

Study completion Jul 31, 2027

Sponsor

Sponsor type
Industry
First posted
Jan 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-arm, open-label, dose-escalation and dose-expanding Phase Ⅰb/Ⅱ clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12 oncolytic adenovirus injection (BioTTT001) in patients with recurrent/progressive high-grade glioma.

Conditions

  • Recurrent High-grade Glioma

Interventions

  • BioTTT001 injectionBiological

    BioTTT001 is administered as a multiple Intratumoral injection. The dose groups to be infusion were 1.0×10\^10 viral particle (VP) ,5.0×10\^10 VP and 2.5×10\^11 VP based on the 3+3 dose escalation principle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: 28 days within BioTTT001 injection
  2. DLT、MTD and/or RP2DTime frame: 28 days within BioTTT001 injection
  3. OS12Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sanbo Brain Hospital, Capital Medical University

    Beijing, Chaoyang District, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.